1. Home
  2. KNSA vs MATX Comparison

KNSA vs MATX Comparison

Compare KNSA & MATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • MATX
  • Stock Information
  • Founded
  • KNSA 2015
  • MATX 1882
  • Country
  • KNSA United Kingdom
  • MATX United States
  • Employees
  • KNSA N/A
  • MATX N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • MATX Marine Transportation
  • Sector
  • KNSA Health Care
  • MATX Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • MATX Nasdaq
  • Market Cap
  • KNSA 2.6B
  • MATX 3.1B
  • IPO Year
  • KNSA 2018
  • MATX N/A
  • Fundamental
  • Price
  • KNSA $41.77
  • MATX $106.23
  • Analyst Decision
  • KNSA Strong Buy
  • MATX Buy
  • Analyst Count
  • KNSA 6
  • MATX 5
  • Target Price
  • KNSA $51.33
  • MATX $143.40
  • AVG Volume (30 Days)
  • KNSA 461.3K
  • MATX 377.6K
  • Earning Date
  • KNSA 10-28-2025
  • MATX 11-04-2025
  • Dividend Yield
  • KNSA N/A
  • MATX 1.35%
  • EPS Growth
  • KNSA N/A
  • MATX 10.58
  • EPS
  • KNSA 0.47
  • MATX 13.11
  • Revenue
  • KNSA $597,973,000.00
  • MATX $3,382,900,000.00
  • Revenue This Year
  • KNSA $62.63
  • MATX N/A
  • Revenue Next Year
  • KNSA $29.93
  • MATX $1.45
  • P/E Ratio
  • KNSA $89.00
  • MATX $8.12
  • Revenue Growth
  • KNSA 55.68
  • MATX 1.88
  • 52 Week Low
  • KNSA $17.82
  • MATX $86.97
  • 52 Week High
  • KNSA $42.93
  • MATX $158.16
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 64.60
  • MATX 55.88
  • Support Level
  • KNSA $39.61
  • MATX $101.98
  • Resistance Level
  • KNSA $42.93
  • MATX $111.15
  • Average True Range (ATR)
  • KNSA 1.43
  • MATX 4.05
  • MACD
  • KNSA 0.19
  • MATX -0.31
  • Stochastic Oscillator
  • KNSA 79.30
  • MATX 50.15

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About MATX Matson Inc.

Matson Inc is engaged in providing ocean transportation and logistics services. The business segments of the company are Ocean Transportation which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific, and Logistics segment which offers long haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.

Share on Social Networks: